Overview

Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
0
Participant gender:
All
Summary
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation of the treatment. The changes of the CNV vascular structure is expected to provide information regarding recurrence. In the eyes that the vascular structure is clearly seen in indocyanine green angiography (ICGA), the vascular changes after ranibizumab injections will be investigated prospectively.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pusan National University Hospital
Collaborator:
Novartis
Treatments:
Ranibizumab
Criteria
Inclusion Criteria:

1. age >= 50

2. Visual acuity of the study eye is between 20/400 and 20/40, and the other eye is
20/400 or better

3. Area of choroidal new vessel (CNV) clearly visible in indocyanine green angiography
(ICGA) is more then 1/2 disc area.

4. Area of CNV clearly visible in ICGA is more than half of the total CNV area.

Exclusion Criteria:

1. CNV caused by other than age-related macular degeneration. (polypoidal choroidal
vascularization, retinal angiomatous proliferation, degenerative myopia etc)

2. Blocked fluorescence in ICGA is more than half of the total CNV area.

3. Disciform scar

4. Previous anti-vascular endothelial growth factor (VEGF) treatment within 3 months

5. Previous any treatment of photodynamic therapy or photocoagulation

6. Previous intraocular or periocular injection of steroid within 3 months

7. Previous intraocular surgery except cataract surgery

8. Vitreo-retinal interface disease on the macula

9. Presence of other diseases may affect visual acuity (uveitis, glaucoma, diabetic
retinopathy, etc.)

10. Uncontrolled periocular or intraocular infection

11. History of hypersensitivity to ranibizumab treatment

12. Uncontrolled systemic diseases (hypertension, diabetes mellitus, etc.)